cycloanthranilylproline: from myxomycete Fuligo candida; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 677114 |
| CHEMBL ID | 388863 |
| CHEBI ID | 181479 |
| SCHEMBL ID | 7270310 |
| MeSH ID | M0472727 |
| Synonym |
|---|
| (s)-(+)-2,3-dihydro-1h-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10h,11ah)-dione |
| (6as)-6a,7,8,9-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine-6,11-dione |
| CHEBI:181479 |
| OPREA1_043936 |
| (s)-(+)-2,3-dihydro-1h-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10h,11ah)-dione, 99% |
| NCGC00160211-01 |
| CHEMBL388863 |
| (11as)-pyrrolo[2,1-c][1,4]benzodiazepine |
| AKOS000773648 |
| SCHEMBL7270310 |
| (11as)-1,2,3,10,11,11a-hexahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5,11-dione |
| (s)-(+)-2,3-dihydro-1h-pyrrolo[2,1-c][1,4]benzodiazapine-5,11(10h,11ah)-dione |
| (s)-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10h)-dione |
| MXBNEEHQIDLPLQ-JTQLQIEISA-N |
| cycloanthranilylproline |
| SR-01000375357-1 |
| sr-01000375357 |
| 138865-23-3 |
| 1h-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10h,11ah)-dione,2,3-dihydro-,hydrate(1:2),(11as)- |
| J-012166 |
| pbd-5,11-dione |
| mfcd00075201 |
| (s)-1,2,3,11a-tetrahydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10h)-dione |
| CS-0324402 |
| 1h-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10h,11ah)-dione, 2,3-dihydro-, (11as)- |
| DTXSID601347283 |
| Class | Description |
|---|---|
| benzodiazepine | A group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID588027 | Displacement of [3H]flunitrazepam from GABAA receptor in rat cortical membrane assessed as [3H]flunitrazepam binding at 100 uM after 90 mins by scintillation counting | 2011 | Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5 | Sugar-based enantiomeric and conformationally constrained pyrrolo[2,1-c][1,4]-benzodiazepines as potential GABAA ligands. |
| AID292979 | Antileishmanial activity against antimony-sensitive Leishmania donovani 200016 promastigotes in bone marrow-derived macrophages assessed as parasite suppression at 100 ug/ml | 2007 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3 | Identification of the benzodiazepines as a new class of antileishmanial agent. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||